Denali Therapeutics Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Denali Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • Denali Therapeutics Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$123M, a 8.25% decline year-over-year.
  • Denali Therapeutics Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$490M, a 189% decline year-over-year.
  • Denali Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$197M, a 42.3% increase from 2022.
  • Denali Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$341M, a 15.2% decline from 2021.
  • Denali Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$296M, a 572% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$490M -$123M -$9.39M -8.25% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$481M -$117M -$287M -168% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$194M -$118M +$3.1M +2.57% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$197M -$133M -$27.2M -25.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$169M -$114M -$6.31M -5.87% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$163M $170M +$232M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$395M -$121M -$54.3M -81.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$341M -$105M -$28.2M -36.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$313M -$107M -$21.9M -25.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$291M -$61.4M +$401K +0.65% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$291M -$66.5M +$4.72M +6.63% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$296M -$77.1M -$321M -132% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $25.4M -$85.6M -$25.5M -42.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $50.9M -$61.8M -$540K -0.88% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $51.5M -$71.2M -$11.3M -18.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $62.7M $244M +$302M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 -$239M -$60.1M -$9.96M -19.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$229M -$61.3M +$1.49M +2.37% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$231M -$60M -$17.5M -41.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$213M -$57.8M -$132M -177% Oct 1, 2019 Dec 31, 2019 10-K 2020-02-27
Q3 2019 -$80.7M -$50.2M -$12.2M -32.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$68.5M -$62.8M -$5.38M -9.38% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 -$63.1M -$42.5M -$16.8M -65.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$46.4M $74.7M +$98.3M Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$145M -$38M -$15.7M -70.3% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$129M -$57.4M -$34.8M -154% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$94.1M -$25.7M -$4M -18.4% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$90.1M -$23.5M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$22.3M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 -$22.6M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 -$21.7M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.